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Background: Although malaria in Brazil almost exclusively occurs within the boundaries of the Amazon Region,
some concerns are raised regarding imported malaria to non-endemic areas of the country, notably increased
incidence of complications due to delayed diagnoses. However, although imported malaria in Brazil represents a
major health problem, only a few studies have addressed this subject.
Methods: A retrospective case series is presented in which 263 medical charts were analysed to investigate the
clinical and epidemiological characterization of malaria cases that were diagnosed and treated at Hospital & Clinics,
State University of Campinas between 1998 and 2011.
Results: Amongst all medical charts analysed, 224 patients had a parasitological confirmed diagnosis of malaria.
Plasmodium vivax and Plasmodium falciparum were responsible for 67% and 30% of the infections, respectively. The
majority of patients were male (83%) of a productive age (median, 37 years old). Importantly, severe complications
did not differ significantly between P. vivax (14 cases, 9%) and P. falciparum (7 cases, 10%) infections.
Conclusions: Severe malaria cases were frequent among imported cases in Brazil outside of the Amazon area. The
findings reinforce the idea that P. vivax infections in Brazil are not benign, regardless the endemicity of the area
studied. Moreover, as the hospital is located in a privileged site, it could be used for future studies of malaria
relapses and primaquine resistance mechanisms. Finally, based on the volume of cases treated and the secondary
complications, referral malaria services are needed in the non-endemic areas of Brazil for a rapid and efficient and
treatment.
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Despite intense global efforts to control malaria, non-
immune and semi-immune travellers living in non-
endemic areas remain a highly vulnerable group for malaria
infection, especially due to delayed diagnosis and increased
risks of complications. Therefore, although the clinical out-
look for malaria in previously healthy adults living in en-
demic areas tends to be mild, the absence of immunity
and delayed or misdiagnosis (up to 40% [1]) may predis-
pose infected persons to more severe presentations in* Correspondence: fabiotmc72@gmail.com
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article, unless otherwise stated.imported cases of disease. Indeed, the chances of death
are 80 to 100 times higher for malaria cases diagnosed
outside of endemic areas [1-3].
Approximately 60% of malaria cases in the Americas
occur in Brazil [4], and these almost exclusively occur in
the Amazon Region. Today, most cases are diagnosed
and treated at the same place where infection was ac-
quired within 48 hours of the onset of symptoms, ac-
cording to the Brazilian Ministry of Health. However,
some regions of the country outside of the Amazon Region
still receive patients presenting with malaria, either from
the Amazon Region or from other countries, mainly Latin
American and African nations. Although malaria is a major
health problem in Brazil, with 177,783 cases registered intral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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cases occur in the Amazon Region), few studies have ana-
lysed the epidemiology and major complications triggered
by this infection outside of endemic areas.
The Hospital & Clinics of the State University of
Campinas (HC-UNICAMP) is one of the fourteen-
referral centers for the diagnosis and treatment of ma-
laria in the Brazilian State of São Paulo. The region was
formerly endemic for malaria, with a great number of
autochthonous cases in the early decades of the 20th
century [5]. In the 1960s, the Malaria Eradication
Campaign led to a sharp drop in the number of autoch-
thonous cases and, from 1980 to 2000, only one autoch-
thonous case was reported in the Campinas region (6) [6].
Here, a retrospective case series is presented that analyses
263 medical charts for the clinical and epidemiological
characteristics of malaria cases treated at HC-UNICAMP
from January 1998 to April 2011.Methods
Ethical approval
The informed consent waiver was approved by the
Research Ethics Committee of the University of Campi-
nas (number 1283/2011).
Study design and subject enrollment
The study was designed as a retrospective case series and
took place at the HC-UNICAMP. Hospital & Clinics, State
University of Campinas (S 22° 49′, W 47° 03′, Campinas,
Brazil) is a tertiary hospital with 409 beds; 471,338 medical
consultations and emergency treatments were performed
in 2012. The hospital has a coverage area of more than
100 municipalities in the areas surrounding Campinas,
which includes a population of 5,000,000 in these munici-
palities [7].
Patients seen at HC-UNICAMP who received a con-
firmed diagnosis of malaria that was reported by its
Hospital Epidemiology Division (NVE-UNICAMP) were
selected. Diagnoses had been confirmed based on analysis
of thick and thin blood films (TBF) that were examined by
trained experienced staff. Patients were enrolled in this
study, regardless of the species of Plasmodium infection
identified, from January 1998 to April 2011. PCR was not
routinely performed to confirm the Plasmodium species
that caused an infection; however a senior microscopist
systematically performed quality control. Only patients
with accessible medical charts were enrolled. A standard
questionnaire was used to register data obtained from the
medical charts, such as demographic profile, time of
clinical disease, referred previous malarial infections,
travel history, peripheral blood parasitaemia, clinical and
laboratory profiles, physical examination and the
prescribed anti-malarial regimen.Malaria patients at HC-UNICAMP are treated follow-
ing the Brazilian guidelines for the treatment of malaria
(Brazilian Ministry of Health, 2010) [8]. Patients were
categorized as severe or non-severe according to 2010
World Health Organization (WHO) criteria [9]. WHO
does not have a guideline to define malaria severity in
infections by P. vivax. Since its absence, Lacerda et al.
[10] argued that the WHO criteria used for P. falci-
parum infection fits malaria severity found in P. vivax
infection. Therefore, the same criteria for both species
were used. Because some patients were treated for ma-
laria at the HC-UNICAMP for two or more episodes of
malaria, only the first confirmed case registered on the
medical chart was considered in the analysis. Patients
were divided into residents (n = 56) and travellers (n = 87)
based on the time that they stayed in the endemic area; a
stay of more than 12 months was characterized as resi-
dence. Differences for which P < 0.05 were considered to
be statistically significant.
Relapses
After treatment, TBF were performed to verify cure.
Blood films were checked at days 15, 45, 75 and 105
after treatment for patients with P. vivax malaria. Re-
lapses were defined as the cases in which, after treat-
ment and a negative TBF, subjects presented a new TBF
with a positive result more than 28 days after starting
anti-malarial treatment. Moreover, a case was only con-
sidered to be a relapse if the patient did not return to an
endemic area during the follow-up period.
Drug regimens
Drug regimens followed Brazilian guidelines for the treat-
ment of malaria (Brazilian Ministry of Health, 2010) [8].
Patients with uncomplicated P. vivax malaria received
non-supervised chloroquine for three days (four pills on
day 1 and three pills on both days 2 and 3) and non-
supervised primaquine (15 mg daily for 14 days). In cases
of true relapse, the dose of primaquine was increased to
22.5 mg/day for 14 days; if there was a second relapse, the
dose was increased to 30.0 mg/day for 14 days. Patients
with uncomplicated P. falciparum malaria received a
single oral mefloquine dose at admission (prior to 2007)
or artesunate plus mefloquine p.o. for three days (2007–
2011). Intramuscular artemether was given to 18 patients
with severe disease. There was no information available
on chemoprophylaxis.
Statistical analyses
Fisher’s exact test was used for categorical data. Stu-
dent’s t-test was used to compare groups with normally
distributed data, and data sets with non-normal distri-
butions were compared using the Mann–Whitney test.
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Amongst a list of 415 subjects obtained from the NVE
in 2011, only 263 patients had charts, of which four
charts could not be retrieved and 35 cases were not con-
firmed as malarial infections after microscopic diagnosis.
Therefore, clinical and epidemiological data were only
retrieved from 224 patients (Figure 1). Plasmodium vivax
malaria accounted for the majority of the cases (n = 151;
67%), while P. falciparum was identified in 67 patients
(30%) and mixed infection (P. vivax + P. falciparum) was
found in only six patients. No cases of infection by other
Plasmodium species were reported. The distribution of
cases per species and year is shown in Figure 2. The ma-
jority of infected people were men (n = 186; 83%) for both
P. vivax and P. falciparum infections (Tables 1 and 2).
Eleven patients (7%) who were at least 30 years old had
diabetes—a proportion very close to that of the Brazilian
population of the same age group—and 17 patients (21%)
who were at least 45 years old had hypertension. Three
patients (1%) had AIDS, and one of these cases had
progressed to severe disease due to P. vivax.
The possible place of infection could be retrieved in
205 cases. Of these, 168 infections (82%) took place in
Brazil and 37 cases were from other countries, those
were called ‘international’ cases, representing 18% of theFigure 1 A flow diagram of medical chart selection. There were 415 na
UNICAMP. Of these, 263 were of patients with medical charts, but 35 of the
not found, so only 224 charts were reviewed.total. The leading foreign country regarding the number
of cases was Angola (13 cases, 6.3%), followed by Haiti
and Guiana (3 cases each), French Guiana, Ghana, Congo
and Mozambique (2 cases each), and Venezuela, Cape
Verde, Guinea Bissau, Equatorial Guinea, Cameroon,
Egypt, South Africa and Papua New Guinea (1 case each).
Malaria clinical complications and severity
Severe malaria was defined according to the WHO cri-
teria [9,10]. Among 21 patients (9%) who presented with
severe malaria, there were 14 cases of P. vivax infec-
tions, seven cases of P. falciparum infections Therefore,
9% of the P. vivax infections and 10% of the P. falciparum
infections evolved into severe disease; these proportions
were not significantly different (P > 0.05). Notably, no pa-
tient with severe disease was a resident of the probable
area of infection, as five months was the longest stay.
Six of the 224 patients (3%) presented with sponta-
neous bleeding of the nose and/or gums. All of these pa-
tients had P. vivax malaria, but no significant difference
for this sign between P. falciparum and P. vivax was found.
Four of these six patients presented thrombocytopaenia
(platelet count <150,000/mm3), which is not a criterion for
severe malaria according to WHO guidelines [9].
From the 41 patients with available urine test data,
eight subjects had haemoglobinuria. These cases inclu-
ded six P. vivax infections (4% of the total P. vivax malaria
cases) and two P. falciparum infections (3% of the total P.
falciparum malaria cases). Among the four patients whomes retrieved from the Center for Epidemiological Surveillance at
m had no confirmed diagnosis of malaria by TBF and 4 charts were
Figure 2 Distribution of cases by Plasmodium species and year. The distribution of cases by year is shown. No association with the total
number of Brazilian cases or any seasonality in the cases was identified. The 2011 cases were recorded until the month of April (n = 224).
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and pCO2 < 35 mmHg) [11], three had P. falciparum
malaria and one had P. vivax malaria.
Hyperbilirubinaemia (total bilirubin >3.0 mg/dL) is
considered to be a marker of severe disease only if it is
associated with another indicator of organ dysfunction
[12]. Following this criterion, five patients presenting
with hyperbilirubinaemia and renal failure were consi-
dered to be patients with severe disease. For renalTable 1 Demographic profile of malaria patients at
HC-UNICAMP in the period 1998-2011
Infectious species
Variable P. falciparum P. vivax Pf/Pv
Freq. (%) Freq (%) Freq. (%)
N 68/224 (30) 150/224 (67) 6/224 (3)
Gender:
Male 59/67 (88)a 124/151 (82) 3/6 (50)a
Female 8/68 (12) 27/150 (18) 3/6 (50)
Age:
Mean ± SD 35 ±13 40 ±16 26 ±18
Median [p25-p75] 35 [26-45]a 39 [28-52]a 19 [15-41]
Ethnicity:
White 45/65 (69) 117/148 (79) 5/6 (83)
Mixed 12/65 (18) 27/148 (18) 1/6 (17)
Black 8/68 (12) 4/148 (3) 0/6 (0)
aP < 0,05.failure, it was considered a creatinine level >1.5 mg/dl
[13,14]. Of note, this value does not correspond to the
WHO criterion for renal failure in severe malaria, and
the patients were considered to have severe malaria for
the concomitant presence of an altered serum creatinine
and serum bilirubin. No patient met the WHO criteria
for severe anemia, cerebral malaria, circulatory collapse,
hypoglycaemia, acidosis or hyperlactataemia.
Malaria relapses
There were 19 (12.6%) cases of true relapses amongst
patients infected with P. vivax infections. For these relapsing
episodes, the drug regimen was either maintained or the
primaquine dose was increased. Among patients with
relapses, four presented no symptoms during the relapse,
four required hospitalization and 14 presented with fever.
Thrombocytopaenia and anaemia were common findings,
occurring in 69% and 60% of patients with relapses, respect-
ively. Most of the relapses resolved after the first retreatment,
but five patients (26%) experienced more than one relapse.
Laboratory admission findings
Thrombocytopaenia (platelet count <150,000/mm3) [15]
was the most common finding in laboratory tests at the
time of diagnosis, affecting 128 of 150 patients (85%).
This proportion did not vary significantly between the
groups with severe or uncomplicated disease or between
Plasmodium species. Twenty-eight patients had severe
thrombocytopaenia (platelet count <50,000/mm3) [16].




P. falciparum P. vivax
Days of symptoms prior to diagnosis N = 53 N = 100
Median [IQR] 4 [3-7] 6 [4-9] 0,0326
Hospitalization (%) 35/67 (52) 30/151 (20) <0,0001
Days of hospitalization N = 35 N = 29
Median [IQR] 4 [2-6] 3 [2-4] 0,1701
Days since return from endemic area N = 40 N = 59
Median [IQR] 10 [5-14] 15 [8-25] 0,0078
Months in endemic area* N = 29 N = 57
Median [IQR] 1 [0,6-4,5] 1 [0,5-2,5] 0,2136
Referred fever (%) 61/67 (91) 125/151 (83) 0,1465
Referred shivers (%) 29/67 (43) 73/151 (48) 0,5569
Referred headache (%) 45/67 (67) 80/151 (53) 0,0550
Referred myalgia (%) 33/67 (49) 69/151 (46) 0,6607
Arthralgia (%) 10/11 (91) 22/32 (69) 0,2370
Vomiting (%) 25/36 (69) 24/44 (55) 0,2488
Sweating (%) 10/14 (71) 17/28 (61) 0,7337
Tachypnea (%) 9/18 (50) 5/12 (42) 0,7220
Jaundice (%) 22/34 (65) 19/46 (41) 0,0448
Splenomegaly (%) 22/43 (51) 20/58 (34) 0,1060
*Only patients considered to be travellers (<12 months in endemic area).
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and 14 were patients with P. falciparum malaria (27%).
The difference between these proportions was not
significantly different (Table 3).
Overall, 52/152 patients (34%) were found to be
anaemic (Hb < 11 mg/dL for females and Hb < 13 mg/dL
for males) [17]. When comparing patients with severe
disease to those with non-severe disease, 57% (16/28) of
patients in the severe group were anemic compared to
29% (36/124) of patients in the non-severe group. The
white blood cell (WBC) count was not different amongst
the different groups of patients and a small proportion
of patients (17%, 25 of 146 patients) were leukopenic.
Laboratory test results were only different between
patients with P. falciparum or P. vivax malaria for
prothrombin time (PT), lactate dehydrogenate (LDH)
and aspartate aminotransferase (AST), were slightly ele-
vated only for LDH and AST in P. falciparum infections
(Table 4). As the sample sizes were small for LDH, a
biomarker that was not part of routine evaluations of
malaria cases, this difference might be biased. No further
investigations were carried out to investigate the diffe-
rence in AST levels.
As expected, a significant decrease in haemoglobin,
haematocrit and red blood cell levels in the first days
after the onset of treatment was detected (P < 0.0001). Asignificant reduction in WBC was also found, but both
median values were within the reference range.
Discussion
The proportion among of Plasmodium species that
caused infection in the present study cohort was diffe-
rent from what is observed in Brazil as a whole (where
P. vivax accounts for nearly 85% of cases), but was very
similar to what has been previously reported for this re-
gion [6,7]. A higher incidence of P. vivax infections,
compared to P. falciparum infections, is different from
what is observed in Europe and the USA, where most
imported cases come from Africa [18-20], but is similar
to what is observed in Australia, where most cases come
from Asia [16,21]. Notably, although the peak of cases
detected in our study in 2004 does not directly mirror
the profile of Brazil, where the highest incidence of
malaria cases took place in 2005; however, 2004 was still
marked by one of the highest number of cases [22].
Otherwise, no special event was found that would fully
explain this pattern.
The high frequency of ‘international’ cases derived from
Angola (34%) probably reflects the fact that both Brazil and
Angola are former Portuguese colonies. The relationship of
imported cases in European countries with their former
African colonies is a well-known phenomenon [23].
Table 3 Laboratory admission values of malaria patients
at HC-UNICAMP during 1998-2011
Variable
Infectious species P
valueP. falciparum P. vivax
Platelets (150-450 × 103/ml) N = 53 N = 93
0,974
83 [46,5-122] 81 [53–109,5]
Haemoglobin (13–17 mg/dl) N = 55 N = 94
0,507
13,2 [12,2-14,5] 13,7 [12,6-14,6]
Haematocrit (42-52%) N = 41 N = 75
0,806
40 [37-42] 40 [36-43]
Erythrocytes (4.5-6.1 × 106/ml) N = 35 N = 75
0,687
4,43 [4,06-4,76] 4,51 [4,11-5,01]
Leukocytes (4-10 × 103/ml) N = 53 N = 91
0,219
5,4 [4,0-6,5] 5,4 [4,3-6,8]
AST (≤37 U/L) N = 43 N = 61
0,029
40 [27-71] 32 [20,5-46]
ALT (≤40 U/L) N = 42 N = 60
0,088
42,5 [24,8-97,2] 31,5 [19,5-61,8]
GGT (≤40 U/L) N = 21 N = 23
0,204
61 [33-200] 58 [23-75]
Total Bilirubin (≤1.0 mg/dl) N = 35 N = 48
0,210
1,60 [0,97-4,98] 1,18 [0,95-2,18]
PT (INR) (≤1.25) N = 28 N = 36
0,015
1,24 [1,1,35] 1,15 [1,06-1,24]
PTT (R) (≤1.30) N = 28 N = 36
0,401
1,20 [1,1,33] 1,14 [1,01-1,32]
LDH (240–479 U/L) N = 11 N = 12
0,013
751 [661-838] 464 [397-552]
Creatinine (0.7-1.3 mg/dl) N = 45 N = 64
0,647
1,07 [0,78-1,22] 0,98 [0,88-1,15]
N refers to the absolute number of patients with the respective laboratory test
information available.
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European studies [24,25], the number of cases associated
with visiting friends and relatives in endemic countries
was very small in the group of ‘international’ cases. Busi-






Hyperbilirrubinaemia + Renal Impairment 6/21 (29)
Respiratory Failure 4/21 (19)
There was no difference in the frequency of clinical signs between the infecting spethe majority of patients infected in former Portuguese
colonies in our study. The lack of patients who had been
infected in African countries during travels to visit friends
and relatives may indicate that the relationships between
two former colonies or a former colony and colonizer
differ.
The higher proportion of infected men, a common
finding among imported malaria studies [26,27], resulted
from the occurrence of most infections when patients
travelled to endemic areas, especially for work-related
reasons. This result could indicate that either men are
employed in jobs associated with the greatest risk of
infection or men still more often occupy the position of
family provider [28]. This is exemplified by the observa-
tion that amongst 111 patients with registered occupa-
tions, 21 (19%) were male truck drivers, an occupation
at risk of infection during trips to endemic areas. Of
some interest was the finding that all cases originating
in Haiti (3 cases) affected Brazilian soldiers who were on
humanitarian deployments for the UN and were also
men of working age.
There was no significant difference in the time elapsed
between the onset of symptoms and the initiation of
treatment when cases of P. falciparum and P. vivax were
compared. The finding that there was no greater time
interval between the onset of symptoms and treatment
for cases of complicated P. vivax or P. falciparum ma-
laria is of critical importance, as it suggests that a longer
disease duration and increased parasitaemia are not suf-
ficient to yield complications of P. vivax malaria, and
the development of severe disease might also depend on
other factors intrinsic to the parasite species [29].
Of particular interest is the finding that no patients
with severe malaria were residents of endemic areas,
which supports the concept of greater vulnerability of
non-immune patients, or those with waning immunity,
to the development of severe presentations of the
disease [1]. This information is of paramount import-
ance, as it serves as a warning to health professionals
and systems located far away from endemic areas to be
alert for patients presenting with signs of malaria, espe-
cially P. vivax malaria, which is still perceived to be aes met at HC-UNICAMP during 1998-2011
Infecting species
P. falciparum P. vivax
Freq (%) Freq (%)
7 (100) 14 (100)
0/7 (0) 6/14 (43)
2/7 (29) 6/14 (43)
3/7 (43) 2/14 (14)
3/7 (43) 1/14 (7)
cies, as calculated with Fisher’s Exact Test.
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failure due to complicated P. vivax malaria, a finding
previously reported in other Brazilian studies [31,32]. Six
patients with P. vivax malaria presented with haemo-
globinuria (4% of P. vivax cases), a rate of incidence
similar to what has been observed previously in a multi-
center study of endemic areas [33], but the proportions
may vary [34] and previous studies on this topic focused
on P. falciparum malaria.
Thrombocytopaenia was a common finding that
affected 85% of patients analysed, a proportion compa-
rable to other studies of imported malaria [16,35]. This
finding reinforces the idea that thrombocytopenia in
patients returning from areas endemic for malaria should
alert a physician to the possibility of this disease. The
prevalence of severe thrombocytopaenia (platelet count
<50,000/mm3) [16] was also relatively high, presenting in
12.5% of patients. The lack of data correlating platelet
levels and bleeding does not prove the absence of an asso-
ciation, as some instances of minor bleeding may have not
been registered in the medical charts. Anaemia was found
in 34% of patients upon admission, a value close to what
has been reported in a previous study on imported malaria
in the Canary Islands [20], in which the majority of cases
were caused by P. falciparum. From the beginning of
treatment of patients with anti-malarials, there was a
reduction in haemoglobin, haematocrit and red blood
cells, as previously reported [36]. This pattern was
observed both in patients with P. falciparum and P.
vivax malaria, and anaemia worsened both in patients
that received chloroquine and primaquine or meflo-
quine and artesunate.
Notably, from 2001 to 2011, there were 2391 cases of
malaria in São Paulo, with 28 deaths caused by malaria
in this state, a lethality rate of 1.1% [37,38]. This lethality
rate is more than 30 times greater than the rate in the
Amazon area, according to official statistics [37]. Never-
theless, no deaths were observed at the HC-UNICAMP
in this study. According to national statistics, there were
three deaths in the region of Campinas during the study
period, resulting in a lethality rate that was similar to
that of the State of São Paulo. Although the lethality of
the cases in Brazil that occurred outside of the Amazon
Region in our study differs from previous studies [2,3],
in which an 80 to 100 times higher lethality rate was
reported, the findings in this study still support the
notion that cases in non-endemic areas of Brazil are
associated with an augmented risk of complications.
Analysing the incidence of relapsing cases along with
associated factors is important for preventing such events.
Relapses are dangerous because of their morbidity and
risk of reintroducing malaria to areas where mosquito
vectors are still present [39]. The occurrence of 12.6%
P. vivax relapses that we found is lower that whatwas previously observed in other studies of imported
malaria in Brazil [40,41], but the lack of monitoring
for a cure after a first bout of treatment and distinct
study methods might account for this difference. The
adequacy of the primaquine dose for the weight of a
patient in the HC-UNICAMP was only adopted after
the study period and this may contribute to a lower
incidence of relapses in the subsequent years. It is also
relevant to highlight that as a reference center for
malaria control in a non-endemic area, the University
of Campinas Hospital is in a privileged location to
study the mechanisms of malaria relapse and the deve-
lopment of primaquine resistance in the future.
There was no information about chemoprophylaxis for
malaria in the medical charts. Thus, it was impossible to
assess different disease severities or the presence of
relapses based on this variable. The absence of such
information might result from the recommendation by
the Ministry of Health that chemoprophylaxis is only
advised for persons travelling to areas with a high inci-
dence of P. falciparum infection, which does not include
most areas of Brazil, but it is important to highlight that
prevention does not solely comprise chemoprophylaxis
[42]. It is important to highlight that current travel advis-
ory services in Campinas are restricted to the UNICAMP
academic community and to medical consultancy in
private companies.
Study limitations
Because this study took place in a tertiary hospital, there
may have been some bias in the selection of patients, as
subclinical or mild disease may have not compelled in-
fected individuals seek out healthcare. Retrospective case
series studies tend to face gaps in the register of infor-
mation and the record of symptoms is somewhat biased
because denied symptoms have a greater chance of not
being registered in the medical chart than referred ones.
Furthermore, it was not possible to exclude, from the
medical charts, the presence of concomitant dengue fever
in all of the cases, and this coinfection could explain cases
of bleeding. Nevertheless, it was not possible to fully
assess the presence of comorbities in all patients enrolled
in the study.
The lack of a more sensitive method for malaria diag-
nosis in this study, especially PCR, makes it impossible
to rule out the presence of mixed infection in the cases
of severe vivax malaria. Nonetheless, TBF are systema-
tically reviewed and a lower incidence of P. falciparum
infection makes coinfection of Plasmodium species less
likely.
Conclusions
This study has gathered much information about malaria
in a region of Brazil outside of the Amazon, a subject
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the peculiarities of Brazilian culture, a concordance of
the social aspects of imported malaria among the cases
studied and of other studies of imported malaria in Latin
America was observed. Based on the clinical and labora-
tory profiles of imported malaria cases in a non-endemic
area of Brazil, infection with P. vivax was found to be
responsible for severe cases. This finding reinforces the
idea that P. vivax infections in Brazil are not benign and
establishes a framework for further research on the topic.
Indeed, more studies are needed on malaria in non-
endemic areas in Brazil, especially with a prospective
design and adequate exclusion of comorbidities and co-
infection. Finally, considering the study area, the volume
of cases treated and the possibility of secondary complica-
tions, the importance of referral malaria services that offer
rapid and efficient diagnosis and treatment in Brazil is
urgently apparent. There is also academic and scientific
value in the study of malaria in non-endemic areas,
because it is only in these areas that cases of relapses due
to P. vivax can be studied without the interference of
potential reinfections.
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